Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in Int-2/High Risk MDS and CMML After HMA Failure
NCT03896269Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daunorubicin + cytarabine liposome in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events (dose-escalation stage) up to 30 days, Maximum-tolerated dose (MTD) of liposome-encapsulated daunorubicin-cytarabine up to 28 days and 2 more. Started May 2019; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03896269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896269.